Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Ipilimumab

Review the clinical trials studying ipilimumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 78

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Status: Active
Location: 660 locations
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy with or without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Status: Active
Location: 441 locations
Testing the Addition of Stereotactic Radiation Therapy with Immune Therapy for the Treatment of Patients with Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Status: Active
Location: 264 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 477 locations
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy with or without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients who are PD-L1 Negative
Status: Active
Location: 151 locations
Testing the Value of Adding Surgery after the Usual Treatment (Immunotherapy) for Patients with Pleural Mesothelioma
Status: Active
Location: 125 locations
Testing Nivolumab with or without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Status: Active
Location: 109 locations
Testing Nivolumab and Ipilimumab Immunotherapy with or without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Status: Active
Location: 90 locations
Immunotherapy in Combination with Prednisone and Sirolimus for Kidney Transplant Recipients with Unresectable or Metastatic Skin Cancer
Status: Active
Location: 25 locations
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Status: Active
Location: 22 locations
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Status: Active
Location: 20 locations
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Status: Active
Location: 17 locations
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Status: Active
Location: 16 locations
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Status: Active
Location: 14 locations
Stereotactic Body Radiation Therapy for the Treatment of Metastatic Renal Cell Carcinoma in Patients with Oligoprogression on Immune Checkpoint Inhibitors
Status: Active
Location: 12 locations
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Status: Active
Location: 9 locations
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Status: Active
Location: 8 locations
An Oncolytic Virus (SVV-001) in Combination with Nivolumab and Ipilimumab for the Treatment of Neuroendocrine Cancers or High-Grade Neuroendocrine Tumors
Status: Active
Location: 8 locations
Nivolumab with or without Ipilimumab before Surgery in Treating Patients with Muscle Invasive Bladder Cancer or High Grade Urothelial Cancer of the Upper Urinary Tract
Status: Active
Location: 7 locations
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Status: Active
Location: 12 locations
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Status: Active
Location: 6 locations
Nivolumab and Ipilimumab with or without Local Consolidation Therapy or Chemotherapy in Treating Patients with Stage IV Non-Small Cell Lung Cancer, LONESTAR Trial
Status: Active
Location: 5 locations
Nivolumab and Ipilimumab for the Treatment of Relapsed or Refractory Pediatric Liver Cancer
Status: Active
Location: 5 locations
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People with Melanoma
Status: Active
Location: 5 locations
Testing the Combination of ZEN003694 and Nivolumab with or without Ipilimumab in Solid Tumors
Status: Active
Location: 6 locations